Tern Plc secures extension on £120,000 loan balance

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that the repayment date of the loan facility agreement originally announced on 12 June 2023 has been extended, with the agreement of the Loan provider, to 11 September 2026.  The Board considers that the extension gives the Company greater negotiating flexibility in relation to funding the future capital requirements of its investee companies.  Since being entered into the Loan has been varied twice previously, as announced on 4 September 2024 and 15 September 2025.

The Company has agreed to make a payment of £38,432.88 to the Loan provider as a partial repayment of the outstanding Loan balance and accrued interest, plus a Loan extension fee of £6,000. Following these payments £120,000 will remain outstanding under the Loan and this amount, plus accrued interest at a rate of 1.00% per calendar month, will be repayable by the Company on or before 11 September 2026.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Device Authority targets cyber resilience opportunity at TechWorks Summit 2026

Device Authority will focus on continuous IoT and OT compliance, AI and quantum risk at TechWorks Summit 2026 as it strengthens its position in connected-device security.

Talking Medicines builds a more defensible AI model for life sciences

Talking Medicines is combining proprietary healthcare intelligence, AI agents and orchestration to build a more specialised AI platform for life sciences.

Search